🔗 Share this article

Elected officials have raised concerns that the United Kingdom's series of deals with Donald Trump are "lacking a solid foundation." This comes after revelations that a so-called "milestone" deal on drug pricing, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond limited headline terms contained within government press releases.

An Agreement in Principle Only

The deal on drug tariffs, described as a "landmark" achievement, exists as an "statement of intent" without detailed provisions. Observers point out that the official announcements from the UK and US governments describe the deal in divergent terms. The British version emphasizes securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for little more than a assurance from President Trump," said David Henig, a trade expert. "We know he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been intensified by Washington's action to put on ice the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an May trade agreement have yet to be formally ratified by the US, despite a looming January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have admitted unease that the government's agreements with the US are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, stated: "The only thing more surprising than the administration's tactics is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have sought to reduce the risk of the US withdrawing from the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is part and parcel of dealing with the Trump administration. However, they maintain that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, delays have emerged in implementing the May tariff agreement. Promised reciprocal agricultural allowances have yet to be finalized, and the commitment to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs staying at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.